St. Jude Medical and CardioMEMS Announce FDA Approval of the CardioMEMS Heart Failure Management System

28 May, 2014

ST. PAUL, Minn. & ATLANTA–(BUSINESS WIRE)– St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, and CardioMEMS, today announced U.S. Food and Drug Administration (FDA) approval of the CardioMEMS™ HF System. The CardioMEMS HF System is the first and only FDA-approved heart failure (HF) monitoring device that has been proven to significantly reduce HF hospital admissions when used by physicians to manage heart failure.

Related News
Boston Millennia Partners Portfolio Company, CardioMEMS HF System Tests Positive
St. Jude Medical’s evaluation of the CardioMEMS Heart Failure (HF) System shows a significant reduction in 30-day hospital readmission rates for patients aged 65 and above. The System is a first-of-its-kind monitoring device that tracks the level of pressure borne by heart-failure patients. Read Full Release
Boston Millennia Partners Portfolio Company, CardioMEMS, Featured on CBS Evening News
A CBS News Boston special report features Millennia Portfolio Company, CardioMEMS', heart failure monitor in use at Brigham and Women's Hospital. Read Full Release
Boston Millennia Partners announces the sale of its portfolio company CardioMEMS to St. Jude Medical
Boston Millennia Partners is pleased to announce that St. Jude Medical (NYSE: STJ) has acquired the remaining 81 percent of CardioMEMS, Inc. it does not own for $375 million dollars. Read Full Release